Gilead ramps up cancer focus with $21 billion Immunomedics deal

Acquiring Immunomedics will give Gilead an immediate presence in the enormous market for drugs that treat solid tumors such as breast cancer, complementing its medicines like Yescarta that are focused on blood tumors.